Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.68 |
| ▸ | MIF | P14174 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43453 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL29586078 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL29708001 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL29429681 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL43452 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL3066472 | 0.98 | ADRB1 (0.66) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Formic Acid SCHEMBL27966100 | 0.90 | ADRB1 (0.58) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL659099 | 0.83 | ADRB2 (0.46) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL10785909 | 0.81 | ADRB1 (0.61) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL921895 | 0.81 | ADRB1 (0.61) | ADRB1ADRA1AMIFHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106905100-B | Resolution method of chiral amine compound and intermediate thereof | 联化科技（台州）有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-106905100-A | The method for splitting and its intermediate of chiral aminated compounds | 联化科技（台州）有限公司 | 2017-06-30 | — | — | CN | claimed |
| US-12428413-B2 | Rho kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-3990442-B1 | RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023129564-A9 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023129564-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| EP-1802583-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | Merck Patent GmbH (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
| WO-2006136538-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINOALKYLPHENOLS | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2006045350-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | MERCK PATENT GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428413-B2 | Rho kinase inhibitors and compositions and methods of use thereof | ROCK1, ROCK2, RHOA | ADRB1 3977/4885ADRA1A 4043/4885MIF 3291/4885 |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | ADRB1 3924/4885ADRA1A 3961/4885MIF 313/4885 |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ADRB1 817/4885ADRA1A 919/4885MIF 4013/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ADRB1 3362/4885ADRA1A 3239/4885MIF 180/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ADRB1 819/4885ADRA1A 917/4885MIF 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.